ESTRO 36 Abstract Book

S526 ESTRO 36 _______________________________________________________________________________________________

Material and Methods Twenty patients with different sites and grades of Soft Tissue Sarcoma underwent surgery and Intraoperative catheter implantations in single plane in biopsy proven Soft tissue sarcoma cases. These patients then underwent High Dose Brachytherapy with Iridium – 192. The patients received average dose of 3.5Gy per Fraction (Two fractions per day 6 hours apart) with total dose of 35 Gy/10 Fr/5 Days and after completion of treatment were followed up at 1 month and later every 3 monthly for 2 years; Followed by 6 monthly interval. Results The Patients were followed up for range of 6 – 42 months (Median 25 months) and overall control rate was 72.72%. The Local recurrence was noted in only one patient (9.09%) and two patients developed distant metastases (18.18%). The dosimetric outcomes were assessed and results analyzed related to the dose to the surrounding organs at risk. The quality of life parameters were also assessed prior to treatment and later during follow ups and results showed better quality of life parameters. Conclusion The results in our study suggested the importance of HDR Brachytherapy in management of Soft Tissue Sarcoma. The local control rate was 72.72 %. The dose of 35Gy over 10 fractions over 5 Days was found to be effective in local control and limb salvage in case of Soft Tissue Sarcoma as practiced at our Centre. PO-0950 High-dose-rate brachytherapy treatment in T1-T2 stage non-melanoma skin cancer patients. M.A. González Ruiz 1 , J. Quirós Rivero 1 , M.F. Ropero Carmona 1 , A. Ruiz Herrero 1 , M.C. Cruz Muñoz 1 , P. Simón Silva 1 , J.J. Cabrera Rodríguez 1 , J.L. Muñoz García 1 , Y. Ríos Kavadoy 1 , F. García Urra 1 , P. Almendras Manzano 2 1 Infanta Cristina Hospital, Radiation Oncology, Badajoz, Spain 2 Infanta Cristina Hospital, Radiophysics, Badajoz, Spain Purpose or Objective To analyze the results in terms of overall survival (OS), cancer specific survival (CSS), local control (LC), cosmesis and toxicity in patients (pts) with non-melanoma skin cancer (NMSC) treated with high-dose-rate brachytherapy (HDR-BT) treatment, plesiotherapy modality; with radical or adjuvant intention in our hospital. Material and Methods Retrospective study of 50 pts with 63 NMSC lesions, T1 (74%) and T2 (26%) stage treated from May 2015 to May 2016. HDR-BT treatment (6 Gy/fraction; total dose 42 Gy) was used in 48 pts with an equivalent 2 Gy dose (EQD2) of 56 Gy. Median total dose of HDR-BT was 42.6 Gy (range 36-50). All the lesions for the selected cases were limited 3-4 mm depth. Treatment intention was radical in 86% pts and adjuvant in 14% pts. The median age of the pts was 76 years-old (range 52-94); 64% males. Basal-cell carcinoma (84%) and face (92,4%) were the most frequent histological type and location respectively. The 34% of the lesions were treated with Valencia applicators and 66% with custom-made moulds. Kaplan-Meier curves have been used for the statistical analysis of survival. Treatment- related toxicity was assessed using RTOG and the NCI- Common Terminology Criteria for Adverse Events guidelines. Results The median follow-up was 18 months (range 7-45). The OS, CSS and LC was 96%, 100% and 96% respectively. The majority of pts had acute skin toxicity grade 1-2. Conjunctival toxicity appeared in 10 % of the pts. Cosmetic results were considered as excellent/good in all patients. Conclusion In patients with NMSC T1 and T2 stage HDR-BT treatment, plesiotherapy modality is a good alternative treatment for non-surgical patients. Plesiotherapy treatment provides

excellent results for local control and cosmesis which is a safe and attractive treatment option. PO-0951 Episcleral Brachytherapy for Uveal Melanoma A. Ponte 1 , T. Teixeira 1 , I. Nobre-Góis 1 , J. Casalta-Lopes 1 , P.C. Simões 1 , A. Cavaco 1 , J. Veríssimo 2 , R. Proença 2 , M. Borrego 1 1 Hospitais da Universidade de Coimbra, Serviço de Radioterapia, Coimbra, Portugal 2 Hospitais da Universidade de Coimbra, Serviço de Oftalmologia, Coimbra, Portugal Purpose or Objective Uveal melanoma is the most common intraocular tumor in the adult age, and the second most common after skin melanoma, with an annual incidence rate of 4-10 per million people. Until November 2013 portuguese patients with uveal melanoma were sent abroad for treatment. Different therapeutic approaches include enucleation, proton therapy, episcleral brachytherapy (EBT), with similar outcomes. The purpose of this work was to evaluate treatment response in patients with uveal melanoma submitted to EBT. Material and Methods Included all patients with uveal melanoma treated in our institution by the Radiation Oncology Department in co- operation with the Ophthalmology Department, between November 2013 and September 2016. Plaques with low energy photon seeds ( 125 I) were used. Dose prescription was 85 Gy to the tumor apex. Response was evaluated by ophthalmic ultrasound with serial lesion measurements and treatment side effects were recorded. A type I error of 0.05 was considered for inferential statistics. Results 50 EBT procedures were done in 50 patients, with a median age of 64 years, female gender (58,0%) and right eye (62,0%) predominance. Initial median diameter and thickness were 12,23 mm (5,92 to 18,70 mm) and 6,73 mm (2,60 to 12,67 mm), respectively. No distant metastatic disease was present at the time of diagnosis. Staging was as follows: Stage IIB 50,0%, Stage IIA 44,0% and Stage IA 4,0%. The median treatment time was 140,7 hours, with a median prescribed dose of 85,90 Gy. A notched eye plaque (ROPES15n) was used in 26,0% of cases. No complications during implant procedure or treatment period were registered. The median follow-up was 10,5 months (1 to 33 months). During this period, a significant reduction in thickness (median difference of 2,035 mm, p<0,001) and diameter (median difference of 2,43 mm, p<0,001) was recorded. Radiation retinopathy was observed in 20,0% of patients, treated by intra-ocular anti-VEGF injection in all cases. Tumor relapse occurred in 2 patients (4,0%) and distant spread in one of these. No cancer related death was EBT is an effective and well tolerated eye sparing method to treat patients with uveal melanomas. A progressive significant reduction in tumors dimension was observed. No severe late side effects was registered, although follow-up time is still limited. registered. Conclusion